Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Medshine Discovery Inc.

Fujian Akeylink Biotechnology Co., Ltd.

Cisen Pharmaceutical Co., Ltd.

Zhejiang Yangli Pharmaceutical Technology Co., Ltd.

Shanghai Jia Tan Pharmatech Co., Ltd.

Zhe Cai

Shuhui Chen

Charles Z Ding

Fei Sun

Jian Li

Wei Luo

Guoping Hu

Wenyuan Qian

Zhaozhong Ding

Zhigang Huang

Dongdong Tang

Yepeng Wang

Provided is an isochroman compound represented by formula (I), or a pharmaceutically acceptable salt thereof, which is used as an aldo-keto reductase (AKR1C3) inhibitor for the treatment of liver cancer.

Isochroman compound

The present invention relates to a structurally novel TLR8 (Toll-like receptor 8) agonist and, in particular, to a compound thereof of formula (I), a pharmaceutically acceptable salt and an isomer thereof.

TLR8 agonist

A TLR8 (Toll-like receptor 8) agonist, a compound of the structure shown in formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.

Disclosed is a crystal form of a hepatitis B surface antigen inhibitor and a preparation method, and an application of the crystal form in the preparation of the hepatitis B surface antigen inhibitor.

Crystal form of hepatitis B surface antigen inhibitor and application thereof

The present invention discloses a benzimidazole-linked indole compound acting as novel divalent IAP antagonist, specifically disclosing the compound shown in formulas (I) or a pharmaceutically acceptable salt thereof. 

Benzimidazole-linked indole compound acting as novel divalent IAP antagonist

Disclosed are a method for preparing a series of novel pyridine derivatives and a use thereof. Such derivatives can be used in the treatment of related diseases caused by mycobacteria, in particular diseases caused by pathogenic mycobacteria, such asand

Growing community of inventors

Shanghai, China

Zhe Cai